WASHINGTON — A leading think tank aligned with the Democratic Party is laying the groundwork for an aggressive slate of efforts to lower drug prices that could be implemented almost immediately, should Joe Biden defeat President Trump in November.

In a report published Thursday, the Center for American Progress focuses on two major policy changes: the first-ever use of a controversial monopoly-busting mechanism known as “march-in-rights” to crack down on companies that overcharge for medicines, and the resurrection of an Obama-era proposal to change how Medicare pays for many drugs administered by doctors. It also lays out a handful of other regulatory tweaks that would not require congressional action.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • March-in rights might work for inventions made by universities using government funding that the university licenses to a commercial entity. There the government plays no part in the license negotiations. Where the government has been a party to an agreement, like with remdesivir, if the government didn’t bargain for price reductions or any other benefits, throwing its weight and taking these concessions after the fact is unfair. It’s frustrating that government negotiators don’t seek a share of commercial benefits for the American people, and that should change. Just not by breaching existing agreements.

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy